Drew Moghanaki: Insights on patients over 75 in the CALGB 140503 study
Drew Moghanaki shared the following on X:
“I’ve been thinking a lot about the patients older than 75 who participated in the CALGB 140503 study and were randomized to lobectomy (n=129). Their 90-day mortality rate was over 3%.
Their 90-day mortality rate was over 3%.
”
Source: Drew Moghanaki/X
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.
He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023